Stonvex
Discover
  • Dashboard
  • World News
  • Stock News
  • Rankings
  • Quant Picks
  • Screener
Markets
  • Heatmap
  • Gainers & Losers
Tools
  • Compare
  • Calendar
  • Community
HomeRankingsScreenerPortfolioCommunity
Stonvex
Log inGet Started
← Back to search

BNTX

Live
Real-time chart · IB-grade AI research · Polygon.io data feed
Set alertSave
  • Overview
  • Financials
  • Filings
  • Short Interest
  • Ownership
  • Ratings
  • Peers
  • Options
  • News
✦
Stonvex AI

BNTX

AI Research Report

Powered by Claude

Ready to analyze BNTX

Runs the full IB-grade framework: Narrative, Reverse DCF, Comps, Sensitivity, and Deal Radar. Takes 20–40 seconds.

Free preview · 3 reports / hour · No sign-up required

Earnings

Next report date, year-over-year trend, and recent quarter history.

Earnings history activates with Polygon. When configured, this panel shows the next report date, consensus EPS/revenue, and the last 4 quarters of actual-vs-estimate.

Quant Grades

6-factor scoring with sector-relative rank. Updated daily.

C+
Stonvex Quant Grade
50.0/ 100
Rank-normalised composite of 6 factors, updated every 60 seconds.
Volume
C+
50 / 100

Today's volume vs prior session average.

Volatility
C+
50 / 100

Absolute daily price move vs peers.

News Flow
C+
50 / 100

24h article count relative to the universe.

Sentiment
C+
50 / 100

AI-classified polarity of recent news.

Dollar Flow
C+
50 / 100

Today's dollar turnover (volume × VWAP).

Relative Strength
C+
50 / 100

Signed daily return vs the rest of the universe.

Financial statements

Most recent quarterly filings sourced directly from SEC EDGAR.

Financial statements activate with Polygon. The Developer plan includes quarterly and annual filings sourced directly from SEC EDGAR.

Corporate events

Similar stocks

View all Biotech →
MRNA
Moderna
$42.80
+5.29%
LLY
Eli Lilly
$810.50
+2.30%
NVO
Novo Nordisk
—
—
REGN
Regeneron
—
—
VRTX
Vertex Pharma
—
—
GILD
Gilead Sciences
—
—
Share this analysis

Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.

Stonvex

AI-powered stock research for US equities.

whgksdhr1111@naver.com

Product

  • Rankings
  • Quant Picks
  • Screener
  • Markets
  • Compare
  • Calendar

Company

  • About Stonvex
  • Pricing & Plans
  • Community
  • Help & FAQ
  • Contact Us

Legal

  • Terms of Service
  • Privacy Policy
  • Privacy Consent
  • Disclaimer
  • Notices & Updates

© 2026 Stonvex. All rights reserved.

This site is for informational purposes only. Not investment advice. Past performance does not guarantee future results.

Latest news

Factor Grades

5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.

Biontech SE

Biontech SE

Biotechnology·NASDAQ NMS - GLOBAL MARKET·DE·IPO 2019-10-10
📅 Earnings in 21d (May 5)
NASDAQ NMS - GLOBAL MARKETAfter-hours
Biontech SE
Biotechnology
$99.63
$2.93 (+3.03%)
After-hrs · vs prev close $96.70
Open
$96.72
Prev close
$96.70
Day range
$95.36 – $99.86
52W range
$79.52 – $124.00
Mkt cap
$24.00B
P/E
—
EPS
$-4.70
Beta
1.37

Factor Grades

View details →
C
Overall score: 48/100
B-
Valuation
C+
Growth
D
Profitability
D+
Momentum
C
Financial Health

Fundamentals

Valuation
Market Cap
$24.00B
P/E (TTM)
—S&P avg ~22
P/S (TTM)
8.46S&P avg ~2.8
P/B
1.02S&P avg ~4.5
P/FCF
18.57S&P avg ~26
EPS (TTM)
$-4.70
Book/sh
$76.49
Cash/sh
$59.20
Profitability
Gross Margin
84.21%avg ~45%
Operating Margin
-15.26%avg ~15%
Net Margin
-13.75%avg ~12%
ROE
-6.05%avg ~18%
ROA
-5.28%avg ~7%
ROI
-5.96%
Payout Ratio
17.60%
FCF/sh
—
Growth & Health
Rev Growth YoY
-11.81%
Rev Growth 5Y
42.88%
EPS Growth YoY
—
EPS Growth 5Y
—
Current Ratio
—
Quick Ratio
7.49
Debt/Equity
—
LT Debt/Eq
—
Trading & Dividends
Beta
1.37
52W High
$124.00
52W Low
$79.52
Avg Vol (10D)
766.8K
Avg Vol (3M)
1.20M
Div Yield
—
Div/sh (TTM)
—
Analyst
Buy (27)
Price Performance
5D+7.90%
MTD+8.80%
3M-2.17%
6M-8.04%
YTD+1.58%
1Y+3.84%

Analyst Consensus

Buy
Based on 27 analysts
Period: 2026-04-01
21 Buy (78%)6 Hold (22%)0 Sell (0%)
Rating Distribution
Strong Buy
6
Buy
15
Hold
6
Sell
0
Strong Sell
0
Trend
2026-04
21/6/0
2026-03
23/5/0
2026-02
24/4/0
2026-01
22/5/0
  • Finnhub·1d ago

    BioNTech and DualityBio's Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer

    MAINZ, Germany - BioNTech SE announced positive results from the primary analysis of a Phase 2 cohort evaluating trastuzumab pamirtecan in patients with HER2-expressing, advanced endometrial cancer...

  • Finnhub·1d ago

    BIONTECH : Berenberg reaffirms its Buy rating

    In a research note published by Harry Gillis, Berenberg advises its customers to buy the stock. The target price is unchanged at USD 155.

  • Benzinga·1d ago

    Elon Musk Questions COVID-19 Vaccine Dosage, Says It Was 'Obviously Too High'

    Elon Musk raises concerns over COVID-19 vaccine dosage, citing a severe reaction that nearly led to hospitalization.

  • Benzinga·1d ago

    Reported Saturday, BioNTech And DualityBio's Trastuzumab Pamirtecan Meets Primary Endpoint With 47.9% Confirmed ORR In HER2-Expressing Recurrent Endometrial Cancer Phase 2 Trial

    Trastuzumab pamirtecan, an investigational HER2-targeted antibody-drug conjugate, met the primary efficacy endpoint in a Phase 2 cohort of heavily pre-treated patients with HER2-expressing, recurrent endometrial cancer,

  • Finnhub·1d ago

    Trastuzumab pamirtecan meets primary efficacy endpoint in phase 2 endometrial cancer cohort

    BioNTech SE: BioNTech and DualityBio's antibody drug conjugate trastuzumab pamirtecan demonstrated clinically meaningful efficacy in patients with HER2-expressing, recurrent endometrial cancer ...

  • Benzinga·7d ago

    Why Is Pfizer Stock Dropping Tuesday?

    Pfizer Inc (NYSE:PFE) shares are trading lower on Tuesday after the company and its COVID-19 vaccine partner paused an updated-shot trial.

  • View all news →
⚠️
Dilution risk detected

1 offering-related filing in the last 60 filings. Latest: 424B3 on 2025-11-14. View all →

No recent insider activity on SEC EDGAR.